pembrolizumab and lenvatinib

Details

Files
Generic Name:
pembrolizumab and lenvatinib
Project Status:
Complete
Therapeutic Area:
Advanced endometrial cancer
Manufacturer:
Merck Canada Inc.
Brand Name:
Keytruda and Lenvima
Project Line:
Reimbursement Review
Project Number:
PC0288-000
Tumour Type:
Gynecology
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Biosimilar:
No
Submission Type:
Initial
Companion Diagnostics:
Yes
Fee Schedule:
Schedule A
Tumour Type:
Genitourinary
Indications:
Keytruda in combination with lenvatinib, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation.
Date NOC Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:

Key Milestones2

Submission receivedMarch 07, 2022
Submission acceptedMarch 21, 2022
Review initiatedMarch 22, 2022
Draft CADTH review report(s) provided to sponsor for commentMay 24, 2022
Deadline for sponsors commentsJune 02, 2022
CADTH review report(s) and responses to comments provided to sponsorJune 30, 2022
Expert committee meeting (initial)July 13, 2022
Draft recommendation issued to sponsorJuly 26, 2022
Draft recommendation posted for stakeholder feedbackAugust 04, 2022
End of feedback periodAugust 18, 2022
Final recommendation issued to sponsor and drug plansSeptember 01, 2022
Final recommendation postedSeptember 20, 2022
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)September 16, 2022
CADTH review report(s) postedDecember 06, 2022